semaglutide type 1 diabetes randomized trial 2024 SELECT Trial

Efficacy and safety of semaglutide 2.4 mg by race and ethnicity: A post hoc analysis of three randomized controlled trials - Rubino - 2024 - Obesity

20.89

★★★★☆4.8 (126)

Semaglutide Use With Automated Insulin Delivery in Adults With Type 1 Diabetes: Qualitative Analyses and Patient-reported Outcomes From a Randomized Controlled Trial

24.97

★★★★★4.9 (98)

Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial

26.83

★★★★★5.0 (157)

New Science Suggests Semaglutide Improves CV Outcomes Beyond Weight Loss

28.03

★★★★★4.7 (84)

And here it is, the long-awaited top story from 2024. Thanks for following our countdown to No. 1! Since the 2017 FDA approval of semaglutide to treat type 2 diabetes and obesity,

22.06

★★★★★4.9 (203)

❓Does #Wegovy (higher dose than #ozempic semaglutide) slow progression of high blood sugar in people with obesity and heart disease obesity but without type 2 #diabetes? ❤️Select Trial showed reduced risk of

20.53

★★★★★5.0 (176)

Semaglutide in patients with overweight or obesity and chronic kidney disease without diabetes: a randomized double-blind placebo-controlled clinical trial

21.83

★★★★★4.8 (132)